Dr. Ann Beliën founded Rejuvenate Biomed in 2017, where she currently functions as CEO. Under her leadership, Rejuvenate Biomed transitioned from a discovery start-up to a clinical-stage biotech company. Ann has successfully attracted international investors, securing funds from seed stage to series B, and built a dedicated and capable team that shares her vision.
Ann brings more than 2 decades of experience in drug development, covering the entire journey from the laboratory bench to the market. She gained this extensive experience through a range of international assignments in the United States, the Netherlands, and Belgium. Ann evolved from scientific roles to operational and strategic positions in various therapeutic areas, including oncology, neurology, immunology, and infectious diseases. She has also been actively involved in external and open innovation, with a focus on therapeutics and prevention. During her career, Ann served as a due diligence representative for R&D at Johnson & Johnson (J&J). She was also a member of the management board of Janssen Prevention Center for a period of five years. She joined J&J in 2000, after completing her postdoctoral research at ETH in Zürich, Switzerland.
Ann brings more than 2 decades of experience in drug development, covering the entire journey from the laboratory bench to the market. She gained this extensive experience through a range of international assignments in the United States, the Netherlands, and Belgium. Ann evolved from scientific roles to operational and strategic positions in various therapeutic areas, including oncology, neurology, immunology, and infectious diseases. She has also been actively involved in external and open innovation, with a focus on therapeutics and prevention. During her career, Ann served as a due diligence representative for R&D at Johnson & Johnson (J&J). She was also a member of the management board of Janssen Prevention Center for a period of five years. She joined J&J in 2000, after completing her postdoctoral research at ETH in Zürich, Switzerland.
Speaking In
3:00 PM - 3:15 PM
Monday, June 5
